-
1
-
-
78751621217
-
Evolving epidemiology of hepatitis C virus
-
Lavanchy, D. Evolving epidemiology of hepatitis C virus Clin. Microbiol. Infect. 2011, 17, 107-115
-
(2011)
Clin. Microbiol. Infect.
, vol.17
, pp. 107-115
-
-
Lavanchy, D.1
-
2
-
-
0024509701
-
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
-
Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362
-
(1989)
Science
, vol.244
, pp. 359-362
-
-
Choo, Q.-L.1
Kuo, G.2
Weiner, A.J.3
Overby, L.R.4
Bradley, D.W.5
Houghton, M.6
-
3
-
-
23944476834
-
Unraveling hepatitis C virus replication from genome to function
-
Lindenbach, B. D.; Rice, M. C. Unraveling hepatitis C virus replication from genome to function Nature 2005, 436, 933-938
-
(2005)
Nature
, vol.436
, pp. 933-938
-
-
Lindenbach, B.D.1
Rice, M.C.2
-
4
-
-
72049091527
-
The efficacy and safety of telaprevir - A new protease inhibitor against hepatitis C virus
-
Gentile, I.; Carleo, M. A.; Borgia, F.; Castaldo, G.; Borgia, G. The efficacy and safety of telaprevir-a new protease inhibitor against hepatitis C virus Expert Opin. Investig. Drugs 2010, 19, 151-159
-
(2010)
Expert Opin. Investig. Drugs
, vol.19
, pp. 151-159
-
-
Gentile, I.1
Carleo, M.A.2
Borgia, F.3
Castaldo, G.4
Borgia, G.5
-
5
-
-
80755159054
-
Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
-
Kwong, D. A.; Kauffman, R. S.; Mueller, P. Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus Nat. Biotechnol. 2011, 29, 993-1003
-
(2011)
Nat. Biotechnol.
, vol.29
, pp. 993-1003
-
-
Kwong, D.A.1
Kauffman, R.S.2
Mueller, P.3
-
6
-
-
67650523017
-
Boceprevir, an NS3 protease inhibitor of HCV
-
Berman, K.; Kwo, P. Y. Boceprevir, an NS3 protease inhibitor of HCV Clin. Liver Dis. 2009, 13, 429-439
-
(2009)
Clin. Liver Dis.
, vol.13
, pp. 429-439
-
-
Berman, K.1
Kwo, P.Y.2
-
7
-
-
78650928878
-
New direct-acting antivirals combination for the treatment of chronic hepatitis C
-
Asselah, T.; Marcellin, P. New direct-acting antivirals combination for the treatment of chronic hepatitis C Liver Int. 2011, 31, 68-77
-
(2011)
Liver Int.
, vol.31
, pp. 68-77
-
-
Asselah, T.1
Marcellin, P.2
-
9
-
-
84901249508
-
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naιve hepatitis C virus genotype 1-infected patients
-
Dieterich, D.; Asselah, T. Y.; Guyader, D.; Berg, T.; Schuchmann, M.; Mauss, S.; Ratziu, V.; Ferenci, P.; Larrey, D.; Maieron, A.; Stern, J. O.; Ozan, M.; Datsenko, Y.; Böcher, W. O.; Steinmann, G. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naιve hepatitis C virus genotype 1-infected patients Antimicrob. Agents Chemother. 2014, 58, 3429-3436
-
(2014)
Antimicrob. Agents Chemother.
, vol.58
, pp. 3429-3436
-
-
Dieterich, D.1
Asselah, T.Y.2
Guyader, D.3
Berg, T.4
Schuchmann, M.5
Mauss, S.6
Ratziu, V.7
Ferenci, P.8
Larrey, D.9
Maieron, A.10
Stern, J.O.11
Ozan, M.12
Datsenko, Y.13
Böcher, W.O.14
Steinmann, G.15
-
10
-
-
84906053496
-
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naιve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomized, double-blind, placebo-controlled trial
-
Jacobson, I. M.; Dore, G. J.; Foster, G. R.; Fried, M. W.; Radu, M.; Rafalsky, V. V.; Moroz, L.; Craxi, A.; Peeters, M.; Lenz, O.; Ouwerkerk-Mahadevan, S.; De La Rosa, G.; Kalmeijer, R.; Scott, J.; Sinha, R.; Beumont-Mauviel, M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naιve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomized, double-blind, placebo-controlled trial Lancet 2014, 384, 403-413
-
(2014)
Lancet
, vol.384
, pp. 403-413
-
-
Jacobson, I.M.1
Dore, G.J.2
Foster, G.R.3
Fried, M.W.4
Radu, M.5
Rafalsky, V.V.6
Moroz, L.7
Craxi, A.8
Peeters, M.9
Lenz, O.10
Ouwerkerk-Mahadevan, S.11
De La Rosa, G.12
Kalmeijer, R.13
Scott, J.14
Sinha, R.15
Beumont-Mauviel, M.16
-
11
-
-
84906059095
-
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naιve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomized, double-blind, placebo-controlled phase 3 trial
-
Manns, M.; Marcellin, P.; Poordad, F.; Stanislau Affonso de Araujo, E.; Buti, M.; Horsmans, Y.; Janczewska, E.; Villamil, F.; Scott, J.; Peeters, M.; Lenz, O.; Ouwerkerk-Mahadevan, S.; De La Rosa, G.; Kalmeijer, R.; Sinha, R.; Beumont-Mauviel, M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naιve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial Lancet 2014, 384, 414-426
-
(2014)
Lancet
, vol.384
, pp. 414-426
-
-
Manns, M.1
Marcellin, P.2
Poordad, F.3
Stanislau Affonso De Araujo, E.4
Buti, M.5
Horsmans, Y.6
Janczewska, E.7
Villamil, F.8
Scott, J.9
Peeters, M.10
Lenz, O.11
Ouwerkerk-Mahadevan, S.12
De La Rosa, G.13
Kalmeijer, R.14
Sinha, R.15
Beumont-Mauviel, M.16
-
12
-
-
84895762620
-
Sofosbuvir: First global approval
-
Keating, G. M.; Vaidya, A. Sofosbuvir: First global approval Drugs 2014, 74, 273-282
-
(2014)
Drugs
, vol.74
, pp. 273-282
-
-
Keating, G.M.1
Vaidya, A.2
-
13
-
-
84896311889
-
Conformation-based restrictions and scaffold replacements in the design of HCV polymerase inhibitor: Discovery of deleobuvir (BI 207127)
-
LaPlante, S. R.; Bös, M.; Brochu, C.; Chabot, C.; Coulombe, R.; Gillard, J. R.; Jakalian, A.; Poirier, M.; Rancourt, J.; Stammers, T.; Thavonekham, B.; Beaulieu, P. L.; Kukolj, G.; Tsantrizos, Y. Conformation-based restrictions and scaffold replacements in the design of HCV polymerase inhibitor: Discovery of deleobuvir (BI 207127) J. Med. Chem. 2014, 57, 1845-1854
-
(2014)
J. Med. Chem.
, vol.57
, pp. 1845-1854
-
-
Laplante, S.R.1
Bös, M.2
Brochu, C.3
Chabot, C.4
Coulombe, R.5
Gillard, J.R.6
Jakalian, A.7
Poirier, M.8
Rancourt, J.9
Stammers, T.10
Thavonekham, B.11
Beaulieu, P.L.12
Kukolj, G.13
Tsantrizos, Y.14
-
14
-
-
84881405876
-
Faldaprevir and deleobuvir for HCV genotype infection
-
Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.-P.; Lohse, A. W.; Müllhaupt, B.; Schuchmann, M.; Bourlière, M.; Buti, M.; Roberts, S. K.; Gane, E. J.; Stern, J. O.; Vinisko, R.; Kukolj, G.; Gallivan, J.-P.; Böcher, W.-O.; Mensa, F. J. Faldaprevir and deleobuvir for HCV genotype infection N. Engl. J. Med. 2013, 369, 630-639
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 630-639
-
-
Zeuzem, S.1
Soriano, V.2
Asselah, T.3
Bronowicki, J.-P.4
Lohse, A.W.5
Müllhaupt, B.6
Schuchmann, M.7
Bourlière, M.8
Buti, M.9
Roberts, S.K.10
Gane, E.J.11
Stern, J.O.12
Vinisko, R.13
Kukolj, G.14
Gallivan, J.-P.15
Böcher, W.-O.16
Mensa, F.J.17
-
15
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
Afdhal, N.; Zeuzem, S.; Kwo, P.; Chojkier, M.; Gitlin, N.; Puoti, M.; Romero-Gomez, M.; Zarski, J.-P.; Agarwal, K.; Buggisch, P.; Foster, G. R.; Bräu, N.; Buti, M.; Jacobson, I. M.; Subramanian, M.; Ding, X.; Mo, H.; Yang, J. C.; Pang, P. S.; Symonds, W. T.; McHutchison, J. G.; Muir, A. J.; Mangia, A.; Marcellin, P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N. Engl. J. Med. 2014, 370, 1889-1898
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
Chojkier, M.4
Gitlin, N.5
Puoti, M.6
Romero-Gomez, M.7
Zarski, J.-P.8
Agarwal, K.9
Buggisch, P.10
Foster, G.R.11
Bräu, N.12
Buti, M.13
Jacobson, I.M.14
Subramanian, M.15
Ding, X.16
Mo, H.17
Yang, J.C.18
Pang, P.S.19
Symonds, W.T.20
McHutchison, J.G.21
Muir, A.J.22
Mangia, A.23
Marcellin, P.24
more..
-
16
-
-
84894297488
-
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection
-
Gane, E. J.; Stedman, C. A.; Hyland, R. H.; Ding, X.; Svarovskaia, E.; Subramanian, G. M.; Symonds, W. T.; McHutchison, J. G.; Pang, P. S. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection Gastroenterology 2014, 146, 736-743
-
(2014)
Gastroenterology
, vol.146
, pp. 736-743
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
Ding, X.4
Svarovskaia, E.5
Subramanian, G.M.6
Symonds, W.T.7
McHutchison, J.G.8
Pang, P.S.9
-
17
-
-
84899068302
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
Feld, J. J.; Kowdley, K. V.; Coakley, E.; Sigal, S.; Nelson, D. R.; Crawford, D.; Weiland, O.; Aguilar, H.; Xiong, J.; Pilot-Matias, T.; DaSilva-Tillmann, B.; Larsen, L.; Podsadecki, T.; Bernstein, B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N. Engl. J. Med. 2014, 370, 1594-1603
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1594-1603
-
-
Feld, J.J.1
Kowdley, K.V.2
Coakley, E.3
Sigal, S.4
Nelson, D.R.5
Crawford, D.6
Weiland, O.7
Aguilar, H.8
Xiong, J.9
Pilot-Matias, T.10
Dasilva-Tillmann, B.11
Larsen, L.12
Podsadecki, T.13
Bernstein, B.14
-
18
-
-
84892761609
-
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naιve patients with HCV genotype 1 infection
-
Everson, G. T.; Sims, K. D.; Rodriguez-Torres, M.; Hézode, C.; Lawitz, E.; Bourlière, M.; Loustaud-Ratti, V.; Rustgi, V.; Schwartz, H.; Tatum, H.; Marcellin, P.; Pol, S.; Thuluvath, P. J.; Eley, T.; Wang, X.; Huang, S.-P.; McPhee, F.; Wind-Rotolo, M.; Chung, E.; Pasquinelli, C.; Grasela, D. M.; Gardiner, D. F. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naιve patients with HCV genotype 1 infection Gastroenterology 2014, 146, 420-429
-
(2014)
Gastroenterology
, vol.146
, pp. 420-429
-
-
Everson, G.T.1
Sims, K.D.2
Rodriguez-Torres, M.3
Hézode, C.4
Lawitz, E.5
Bourlière, M.6
Loustaud-Ratti, V.7
Rustgi, V.8
Schwartz, H.9
Tatum, H.10
Marcellin, P.11
Pol, S.12
Thuluvath, P.J.13
Eley, T.14
Wang, X.15
Huang, S.-P.16
McPhee, F.17
Wind-Rotolo, M.18
Chung, E.19
Pasquinelli, C.20
Grasela, D.M.21
Gardiner, D.F.22
more..
-
19
-
-
84904602144
-
Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: The C-WORTHY study
-
Lawitz, E.; Hezode, C.; Gane, E.; Tam, E.; Lagging, M.; Balart, L.; Rossaro, L.; Ghalib, R.; Shaughnessy, M.; Hwang, P.; Wahl, J.; Robertson, M. N.; Haber, B. Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: The C-WORTHY study J. Hepatol. 2014, 60, S25-S26
-
(2014)
J. Hepatol.
, vol.60
, pp. 25-S26
-
-
Lawitz, E.1
Hezode, C.2
Gane, E.3
Tam, E.4
Lagging, M.5
Balart, L.6
Rossaro, L.7
Ghalib, R.8
Shaughnessy, M.9
Hwang, P.10
Wahl, J.11
Robertson, M.N.12
Haber, B.13
-
20
-
-
67649303095
-
Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection
-
Beaulieu, P. L. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection Expert Opin.Ther. Pat. 2009, 19, 145-164
-
(2009)
Expert Opin.Ther. Pat.
, vol.19
, pp. 145-164
-
-
Beaulieu, P.L.1
-
21
-
-
77954628601
-
HCV NS5B polymerase inhibitors
-
Watkins, W. J.; Ray, A. S.; Chong, L. S. HCV NS5B polymerase inhibitors Cur. Opin. Drug Discovery Dev. 2010, 13, 441-465
-
(2010)
Cur. Opin. Drug Discovery Dev.
, vol.13
, pp. 441-465
-
-
Watkins, W.J.1
Ray, A.S.2
Chong, L.S.3
-
22
-
-
84858722318
-
Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase
-
Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase J. Med. Chem. 2012, 55, 2532-2531
-
(2012)
J. Med. Chem.
, vol.55
, pp. 2532-2531
-
-
Sofia, M.J.1
Chang, W.2
Furman, P.A.3
Mosley, R.T.4
Ross, B.S.5
-
23
-
-
67649625180
-
Progress towards improving antiviral therapy for hepatitis C virus polymerase inhibitors. Part 1: Nucleoside analogues
-
Brown, N. A. Progress towards improving antiviral therapy for hepatitis C virus polymerase inhibitors. Part 1: Nucleoside analogues Expert Opin. Investig. Drugs 2009, 18, 709-725
-
(2009)
Expert Opin. Investig. Drugs
, vol.18
, pp. 709-725
-
-
Brown, N.A.1
-
24
-
-
77953463393
-
Nucleoside analog inhibitors of hepatitis C virus replication: Recent advances, challenges and trends
-
Furman, P. A.; Lam, A. M.; Murakami, E. Nucleoside analog inhibitors of hepatitis C virus replication: Recent advances, challenges and trends Future Med. Chem. 2009, 1, 1429-1452
-
(2009)
Future Med. Chem.
, vol.1
, pp. 1429-1452
-
-
Furman, P.A.1
Lam, A.M.2
Murakami, E.3
-
25
-
-
84863110363
-
Nucleotide prodrugs for HCV therapy
-
Sofia, M. J. Nucleotide prodrugs for HCV therapy Antiviral Chem. Chemother. 2011, 22, 23-49
-
(2011)
Antiviral Chem. Chemother.
, vol.22
, pp. 23-49
-
-
Sofia, M.J.1
-
26
-
-
0345188811
-
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
-
Lohmann, V.; Körner, F.; Koch, J. O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
-
(1999)
Science
, vol.285
, pp. 110-113
-
-
Lohmann, V.1
Körner, F.2
Koch, J.O.3
Herian, U.4
Theilmann, L.5
Bartenschlager, R.6
-
27
-
-
84866332769
-
Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity inpatients chronically infected with genotype 1 hepatitis C virus (HCV)
-
Beaulieu, P. L.; Bös, M.; Cordingley, M. G.; Chabot, C.; Fazal, G.; Garneau, M.; Fillard, J. R.; Jolicoeur, E.; LaPlante, S.; McKercher, G.; Poirier, M.; Poupart, M.-A.; Tsantrizos, Y. S.; Duan, J.; Kukolj, G. Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity inpatients chronically infected with genotype 1 hepatitis C virus (HCV) J. Med. Chem. 2012, 55, 7650-7666
-
(2012)
J. Med. Chem.
, vol.55
, pp. 7650-7666
-
-
Beaulieu, P.L.1
Bös, M.2
Cordingley, M.G.3
Chabot, C.4
Fazal, G.5
Garneau, M.6
Fillard, J.R.7
Jolicoeur, E.8
Laplante, S.9
McKercher, G.10
Poirier, M.11
Poupart, M.-A.12
Tsantrizos, Y.S.13
Duan, J.14
Kukolj, G.15
-
28
-
-
61849172935
-
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment
-
Erhardt, A.; Deterding, K.; Benhamou, Y.; Reiser, M.; Forns, X.; Pol, S.; Calleja, J. L.; Ross, S.; Spangenberg, H. C.; Garcia-Samaniego, J.; Fuchs, M.; Enriquez, J.; Wiegand, J.; Stern, J.; Wu, K.; Kukolj, G.; Marquis, M.; Beaulieu, P.; Nehmiz, G.; Steffgen, J. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment Antiviral Ther. 2009, 14, 23-32
-
(2009)
Antiviral Ther.
, vol.14
, pp. 23-32
-
-
Erhardt, A.1
Deterding, K.2
Benhamou, Y.3
Reiser, M.4
Forns, X.5
Pol, S.6
Calleja, J.L.7
Ross, S.8
Spangenberg, H.C.9
Garcia-Samaniego, J.10
Fuchs, M.11
Enriquez, J.12
Wiegand, J.13
Stern, J.14
Wu, K.15
Kukolj, G.16
Marquis, M.17
Beaulieu, P.18
Nehmiz, G.19
Steffgen, J.20
more..
-
29
-
-
33747364216
-
Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds
-
Beaulieu, P. L.; Gillard, J.; Bykowski, D.; Brochu, C.; Dansereau, N.; Duceppe, J.-S.; Haché, B.; Jakalian, A.; Lagacé, L.; LaPlante, S.; McKercher, G.; Moreau, E.; Perreault, S.; Stammers, T.; Thauvette, L.; Warrington, J.; Kukolj, G. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds Bioorg. Med. Chem. Lett. 2006, 16, 4987-4993
-
(2006)
Bioorg. Med. Chem. Lett.
, vol.16
, pp. 4987-4993
-
-
Beaulieu, P.L.1
Gillard, J.2
Bykowski, D.3
Brochu, C.4
Dansereau, N.5
Duceppe, J.-S.6
Haché, B.7
Jakalian, A.8
Lagacé, L.9
Laplante, S.10
McKercher, G.11
Moreau, E.12
Perreault, S.13
Stammers, T.14
Thauvette, L.15
Warrington, J.16
Kukolj, G.17
-
30
-
-
1442283032
-
Specific inhibitors of HCV polymerase identified using a NS5B with lower affinity for template/primer substrate
-
McKercher, G.; Beaulieu, P. L.; Lamarre, D.; LaPlante, S.; Lefebvre, S.; Pellerin, C.; Thauvette, L.; Kukolj, G. Specific inhibitors of HCV polymerase identified using a NS5B with lower affinity for template/primer substrate Nucleic Acids Res. 2004, 32, 422-431
-
(2004)
Nucleic Acids Res.
, vol.32
, pp. 422-431
-
-
McKercher, G.1
Beaulieu, P.L.2
Lamarre, D.3
Laplante, S.4
Lefebvre, S.5
Pellerin, C.6
Thauvette, L.7
Kukolj, G.8
-
31
-
-
84918529786
-
-
WO Patent WO 03/010141
-
Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J. WO Patent WO 03/010141, 2003.
-
(2003)
-
-
Beaulieu, P.L.1
Fazal, G.2
Goulet, S.3
Kukolj, G.4
Poirier, M.5
Tsantrizos, Y.6
Jolicoeur, E.7
Gillard, J.8
Poupart, M.-A.9
Rancourt, J.10
-
32
-
-
77956301340
-
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)
-
Llinàs-Brunet, M.; Bailey, M. D.; Goudreau, N.; Bhardwaj, P. K.; Bordeleau, J.; Bös, M.; Bousquet, Y.; Cordingely, M. G.; Duan, J.; Forgione, P.; Garneau, M.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Kawai, S. H.; Naud, J.; Poupart, M.-A.; White, P. W. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) J. Med. Chem. 2010, 53, 6466-6476
-
(2010)
J. Med. Chem.
, vol.53
, pp. 6466-6476
-
-
Llinàs-Brunet, M.1
Bailey, M.D.2
Goudreau, N.3
Bhardwaj, P.K.4
Bordeleau, J.5
Bös, M.6
Bousquet, Y.7
Cordingely, M.G.8
Duan, J.9
Forgione, P.10
Garneau, M.11
Ghiro, E.12
Gorys, V.13
Goulet, S.14
Halmos, T.15
Kawai, S.H.16
Naud, J.17
Poupart, M.-A.18
White, P.W.19
-
33
-
-
63549101398
-
Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication
-
Vaillancourt, F. H.; Pilote, L.; Cartier, M.; Lippens, J.; Liuzzi, M.; Bethell, R. C.; Cordingley, M. G.; Kukolj, G. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication Virology 2009, 387, 5-10
-
(2009)
Virology
, vol.387
, pp. 5-10
-
-
Vaillancourt, F.H.1
Pilote, L.2
Cartier, M.3
Lippens, J.4
Liuzzi, M.5
Bethell, R.C.6
Cordingley, M.G.7
Kukolj, G.8
-
34
-
-
78049365437
-
Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B
-
LaPlante, S. R.; Gillard, J. R.; Jakalian, A.; Aubry, N.; Coulombe, R.; Brochu, C.; Tsantrizos, Y. S.; Poirier, M.; Kukolj, G.; Beaulieu, P. L. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B J. Am. Chem. Soc. 2010, 132, 15204-15212
-
(2010)
J. Am. Chem. Soc.
, vol.132
, pp. 15204-15212
-
-
Laplante, S.R.1
Gillard, J.R.2
Jakalian, A.3
Aubry, N.4
Coulombe, R.5
Brochu, C.6
Tsantrizos, Y.S.7
Poirier, M.8
Kukolj, G.9
Beaulieu, P.L.10
-
35
-
-
84855427261
-
Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor
-
Duan, J.; Yong, C.-L.; Garneau, M.; Amad, M.; Bolger, G.; De Marte, J.; Montpetit, H.; Otis, F.; Jutras, M.; Rhéaume, M.; White, P. W.; Llinàs-Brunet, M.; Bethell, R. C.; Cordingley, M. G. Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor Xenobiotica 2012, 42, 164-172
-
(2012)
Xenobiotica
, vol.42
, pp. 164-172
-
-
Duan, J.1
Yong, C.-L.2
Garneau, M.3
Amad, M.4
Bolger, G.5
De Marte, J.6
Montpetit, H.7
Otis, F.8
Jutras, M.9
Rhéaume, M.10
White, P.W.11
Llinàs-Brunet, M.12
Bethell, R.C.13
Cordingley, M.G.14
-
36
-
-
84866314278
-
The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in human
-
Duan, J.; Bolger, G.; Garneau, M.; Amad, M.; Batonga, J.; Montpetit, H.; Otis, F.; Jutras, M.; Lapeyre, N.; Rhéaume, M.; Kukolj, G.; White, P. W.; Bethell, R. C.; Cordingley, M. G. The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in human Antimicrob. Agents Chemother. 2012, 56, 5381-5386
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 5381-5386
-
-
Duan, J.1
Bolger, G.2
Garneau, M.3
Amad, M.4
Batonga, J.5
Montpetit, H.6
Otis, F.7
Jutras, M.8
Lapeyre, N.9
Rhéaume, M.10
Kukolj, G.11
White, P.W.12
Bethell, R.C.13
Cordingley, M.G.14
-
37
-
-
33645840463
-
A rational for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
-
Müller, L.; Mauthe, R. J.; Riley, C. M.; Andino, M. M.; De Antonis, D.; Beels, C.; DeGeorge, J.; De Knaep, A. G. M.; Ellison, D.; Fagerland, J. A.; Frank, R.; Fritschel, B.; Galloway, S.; Harpur, E.; Humfrey, C. D. N.; Jacks, A. S.; Jagota, N.; Mackinnon, J.; Mohan, G.; Ness, D. K.; ODonovan, M. R.; Smith, M. D.; Vudathala, G.; Yotti, L. A rational for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity Regul. Toxicol. Pharmacol. 2006, 44, 198-211
-
(2006)
Regul. Toxicol. Pharmacol.
, vol.44
, pp. 198-211
-
-
Müller, L.1
Mauthe, R.J.2
Riley, C.M.3
Andino, M.M.4
De Antonis, D.5
Beels, C.6
Degeorge, J.7
De Knaep, A.G.M.8
Ellison, D.9
Fagerland, J.A.10
Frank, R.11
Fritschel, B.12
Galloway, S.13
Harpur, E.14
Humfrey, C.D.N.15
Jacks, A.S.16
Jagota, N.17
Mackinnon, J.18
Mohan, G.19
Ness, D.K.20
Odonovan, M.R.21
Smith, M.D.22
Vudathala, G.23
Yotti, L.24
more..
-
38
-
-
1542771886
-
Tetracycline studies. Part 5. New syntheses of anthracenes and anthraquinones through benzophenone carbanions
-
Broadhurst, M. J.; Hassall, C. H.; Thomas, G. J. Tetracycline studies. Part 5. New syntheses of anthracenes and anthraquinones through benzophenone carbanions J. Chem. Soc., Perkin 1 Trans. 1977, 2502-2512
-
(1977)
J. Chem. Soc., Perkin 1 Trans.
, pp. 2502-2512
-
-
Broadhurst, M.J.1
Hassall, C.H.2
Thomas, G.J.3
|